Cargando…
The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis
Autores principales: | van Leeuwen, Jolijn R, Hafemann, Sophia, van der Boog, Paul, van der Woude, Diane, Rabelink, Ton, Teng, Y K Onno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690075/ https://www.ncbi.nlm.nih.gov/pubmed/38045999 http://dx.doi.org/10.1093/ckj/sfad225 |
Ejemplares similares
-
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023) -
Overlap Syndrome Consisting of Polymyositis/Dermatomyositis and ANCA-Associated Vasculitis According to the 2022 ACR/EULAR Criteria for Vasculitis: A Korean Single-Centre Study
por: Ha, Jang Woo, et al.
Publicado: (2023) -
Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria
por: Pyo, Jung Yoon, et al.
Publicado: (2023) -
Response to “Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis and Concominant Complement System Activation”
por: van Leeuwen, Jolijn R., et al.
Publicado: (2022) -
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)